期刊文献+

西罗莫司血药浓度测定方法的建立及在肝移植患者中的应用 被引量:3

Determination of sirolimus in human whole blood by HPLC and the exploratory in liver transplantation
下载PDF
导出
摘要 目的建立高效液相色谱法测定西罗莫司血药浓度,测定该药在肝移植患者中的药代动力学参数。方法以沉淀-萃取法处理全血样品,采用Hypersil ODS C18(250 mm×4.6 mm,5μm)柱,柱温为50℃,乙腈-甲醇-水(7.5:62.5:30)为流动相,流速1.2 mL/min,以32-去甲基雷帕霉素为内标,在276 nm波长处,检测西罗莫司血药浓度,并应用此方法测定5例肝移植患者的西罗莫司血药浓度。结果全血中西罗莫司浓度在2.0~50.0ng/mL范围内线性良好(r=0.999 7),平均相对回收率为99.1%(n=5)。5例肝移植患者的Cmax为(12.66±4.1)ng/mL,t1/2为(19.2±11.2)h,tmax为(1.8±0.3)h。结论本方法快速、简便、准确,灵敏度高,重现性好,可用于肝移植患者的西罗莫司临床药物监测。 Objective To establish an HPLC method to determine the concentration of sirolimus in whole blood. Methods The whole-blood samples were pretreated by precipitation-extraction method,and sirolimus was determined by HPLC-UV.Hypersil ODS C18 analysis column(250 mm×4.6 mm,5 μm)was used,and the temperature was set at 50 ℃.The mobile phase was a mixture of acetonitrile-methanol-water(7.5:62.5:30)with a flow rate of 1.2 mL/min.The detection wavelength was set at 276 nm. Results The calibration curve was linear within the range 2.0~50 ng/mL(r=0.999 7).The mean relative recovery was 99.1%,and the mean absolute recovery was 82.2%(n=5).The intra-day and the inter-day relative standard deviation did not exceed 3.3% and 6.3% respectively.In the five transplantation receptors,Cmax was(12.66±4.1)ng/mL,t1/2 was(19.2±11.2)h,tmax was(1.8±0.3)h. Conclusion This method is simple,rapid,sensitive and suitable for therapeutic drug monitoring of sirolimus.
出处 《实用药物与临床》 CAS 2011年第1期28-30,共3页 Practical Pharmacy and Clinical Remedies
关键词 西罗莫司 高效液相色谱法 血药浓度 肝移植 Sirolimus HPLC Plasma drug concentration Liver transplantation
  • 相关文献

参考文献3

二级参考文献37

  • 1万征,蔡衡,李晓春,林青,张文娟.雷帕霉素药物洗脱支架的临床应用研究[J].天津医药,2004,32(9):551-553. 被引量:1
  • 2王长希,郑克立,赵亮,陈立中,费继光,刘龙山.西罗莫司用于肾移植患者的临床前瞻性研究[J].世界临床药物,2005,26(1):55-57. 被引量:5
  • 3庞明杰,赵燕,张宏.雷帕霉素药物涂层支架治疗分叉病变不同方法的对比[J].中国误诊学杂志,2005,5(4):610-611. 被引量:2
  • 4李坚,王洪林.肝癌肝移植术后肝癌复发的研究进展[J].中华外科杂志,2005,43(11):753-756. 被引量:21
  • 5Morales JM, Wramner L, Kreis H, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients[J]. Am J Transplant,2002,2(5) :436-442.
  • 6Sehgal SN, Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression [J]. Clin Biochem,2006,39(5):484-489.
  • 7Fung J, Kelly D, Kadry Z, et al. Immunosuppression in liver transplantation: beyond ca|cineurin inhibitors[J]. Liver Transpl, 2005 : 11 (3) : 267-280.
  • 8Soliman GA. The mammalian target of rapamycin signaling network and gene regulation [J]. Curr Opin Lipidol,2005,16(3): 317-323.
  • 9Vignot S, Faivre S, Aguirre D, et al. roTOR-targeted therapy of cancer with rapamycin derivatives[J]. Ann Oncol,2005,16 (4) : 525-537.
  • 10Cheng-Lai A, Frishman WH. Sirolimus-eluting coronary stents: novel devices for the management of coronary artery disease[J]. Am J Ther,2004,11(3):218-228.

共引文献8

同被引文献35

  • 1杨杰.高效液相色谱仪检测器进展及其在药物分析中的应用[J].实用药物与临床,2007,10(3):187-188. 被引量:11
  • 2罗继名,张永东,肖云彬,林杰,李嫩祥.高效液相色谱法测定人血浆中司帕沙星药物浓度[J].实用药物与临床,2007,10(4):252-253. 被引量:3
  • 3Sun L, Liang C, Shirazian S, et al. Discovery of 5- [ 5-fluoro-2-oxo- 1,2-dihydroindol-( 3 Z ) -ylidenemethyl ] -2,4-dimethyl-1 H-pyrrole- 3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem, 2003,46 ( 7 ) : 1116-1119.
  • 4Goodman VL, Rock EP, Dagher R, et al. Approval summary:sunitinib for the treatment of imatinib refractory or intolerant gastro-intestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res, 2007,13 ( 5 ) : 1367 -1373.
  • 5Ikeda K, Ikawa K, Ikeda A, et al. A simple and rapid determination of biapenem in plasma by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci, 2006,844 ( 1 ) : 148-152.
  • 6Gomy M, Rtihm S, Laer S, et al. Pharmacogenomic adaptation of antiretroviral therapy: overcoming the failure of lopinavir in an African infant with CYP2D6 ultrarapid metabolism. Eur J Clin Pharmaeol, 2010,66( 1 ) : 107-108.
  • 7Rodamer M, Elsinghorst PW, Kinzig M, et al. Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification ofsunitinib ( SUl1248 ) and its active metabolite, N-desethyl sunitinib (SU12662), in human plasma: application to an explorativestudy. J Chromatogr B Analyt Teehnol Biomed Life Sci,2011,879(11-12) :695-706.
  • 8陈忠华.在体移植免疫实验研究应注意的几个问题[J].中华器官移植杂志,2002,23:4-5.
  • 9Gunthart M, Kearns-Jonker M. Gene therapy for the induction of chimerism and transplant tolerance[J]. Curr Gene Ther,2007, 7(6) :411-20.
  • 10Forman D, Tian C, Iacomini J. Induction of donor-specific tolerance in sublethally irradiated recipients by gene therapy [J]. Mol Ther,2005,12(2) :353-359.

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部